Inish M. O’Doherty, PhD, is a Director of Consortia Science Support at C-Path. In this role, he works to develop new consortia, including the Type 1 Diabetes (T1D) and Therapeutic Transplant (TTC) Consortia. Specifically, his work focuses on the collaborative selection and development of prognostic biomarkers that can be qualified as Drug Development Tools (DDT) and Novel Methodologies (NO) with the FDA and EMA respectively.
Prior to C-Path, Dr. O’Doherty spent a number of years implementing chemical biology target validation methodologies in the drug discovery and development process at Pfizer Inc. During his tenure at Pfizer, his work spanned both the chemistry and biological sides of early-stage drug discovery. He worked at both the Worldwide Medicinal Chemistry Oncology branch in La Jolla, CA, and the Cardiovascular Metabolic and Endocrine Disease (CVMED) Research Unit in Cambridge, MA. As well as leading in-house target validation and target-engagement studies, Dr. O’Doherty was the Pfizer scientific lead for an academic collaboration with the University of California San Francisco to advance the understanding of quantitative in-cell target engagement assays in complex cellular environments.
Dr. O’Doherty received his PhD from Cornell University, Ithaca, as part of the Tri-institutional training Program in Chemical Biology (TPCB) which encompasses Weill Cornell Medical College, The Rockefeller University, and Memorial Sloan-Kettering Cancer Center. Inish worked on a variety of interdisciplinary projects, which focused on the design and application of chemical probes for the deconvolution biological signaling pathways, with collaborators across serval institutions, resulting a number of publications.